Skip to main content

Peptide dosage charts and schedules

Choose a compound to see where its dose comes from. Find approved schedules, doses studied in trials and reported ranges, with their limits explained. For a prescribed brand, use its own product guide.

Find a compound dosage guide

FDA label schedules

Published steps from an approved product label.

  • Semaglutide

    Approved label · 5 schedule steps

    Chart covers 0.25–2.4 mg

    FDA label
  • Tirzepatide

    Approved label · 6 schedule steps

    Chart covers 2.5–15 mg

    FDA label

Schedules that depend on the product

The same ingredient can have different doses for different products or uses.

  • Liraglutide

    Product labels · 2 products

    Victoza ≤1.8 mg · Saxenda ≤3 mg

    FDA label

Doses studied in human trials

Amounts tested in study groups. These are not approved treatment schedules.

  • Cagrilintide

    Human trial · 5 study groups

    Chart covers 0.3–4.5 mg

    Human trial
  • Eloralintide

    Human trial · 6 study groups

    Chart covers 1–9 mg

    Human trial
  • Mazdutide

    Human trial · 2 study groups

    Chart covers 4–6 mg

    Human trial
  • Pemvidutide

    Human trial · 3 study groups

    Chart covers 1.2–2.4 mg

    Human trial
  • Retatrutide

    Human trial · 4 study groups

    Chart covers 1–12 mg

    Human trial
  • Survodutide

    Human trial · 4 study groups

    Chart covers 0.6–4.8 mg

    Human trial
  • VK2735

    Human trial · 4 study groups

    Chart covers 2.5–15 mg

    Human trial

Reported ranges

Amounts described in the sources, with the limits of those reports stated in each guide.

  • AOD-9604

    Reported range

    limited human data
  • BPC-157

    Reported range

    no human dose shown to work
  • CJC-1295

    Reported range

    limited human data
  • Hexarelin

    Reported range

    limited human data
  • IGF-1 LR3

    Reported range

    no human dose shown to work
  • Ipamorelin

    Reported range

    Human trial
  • PEG-MGF

    Reported range

    no human dose shown to work
  • Sermorelin

    Reported range

    limited human data

No established dose

Read what is known and which dose information is missing.

  • AHK-Cu

    No established dose

    no human dose shown to work
  • Brenipatide

    No established dose

    no human dose shown to work
  • DSIP

    No established dose

    limited human data
  • Enicepatide

    No established dose

    Human trial
  • Epitalon

    No established dose

    limited human data
  • GHK-Cu

    No established dose

    indirect evidence
  • Kisspeptin-10

    No established dose

    limited human data
  • KPV

    No established dose

    no human dose shown to work
  • LL-37

    No established dose

    limited human data
  • Macupatide

    No established dose

    Human trial
  • MariTide

    No established dose

    Human trial
  • Melanotan II

    No established dose

    limited human data
  • MOTS-c

    No established dose

    no human dose shown to work
  • NAD+

    No established dose

    limited human data
  • Petrelintide

    No established dose

    Human trial
  • Pinealon

    No established dose

    limited human data
  • PT-141

    No established dose

    FDA label
  • Selank

    No established dose

    limited human data
  • Semax

    No established dose

    limited human data
  • SS-31

    No established dose

    FDA label
  • TB-500

    No established dose

    indirect evidence
  • Tesamorelin

    No established dose

    FDA label
  • Thymosin alpha-1

    No established dose

    limited human data
  • Zenagamtide

    No established dose

    Human trial

Find your brand’s dosage guide

The ingredient alone does not tell you the dose. Brand labels set different starting doses, limits and timing. Open the full guide for the steps, approved uses and age limits.

Brand starting doses and label maximums, with the form and timing of each product. These are separate schedules, not equivalent doses.
ProductStarting doseLabel maximum

Semaglutide · Once weekly

Subcutaneous injection in the abdomen, thigh or upper arm

0.25 mg7.2 mg

Only weight reduction in adults can reach 7.2 mg. The label asks for at least 4 weeks at 2.4 mg first, and for a clinical reason to go further. The FDA added this dose on 2026-03-19.

Semaglutide · Once weekly

Subcutaneous injection in the abdomen, thigh or upper arm

0.25 mg2 mg

2 mg once weekly is the maximum recommended dosage. It was not on the original label: the FDA added it as a third maintenance dose on 2022-03-28.

Tirzepatide · Once weekly

Subcutaneous injection in the abdomen, thigh or upper arm

2.5 mg15 mg

15 mg once weekly is the maximum for every approved use of Zepbound. The label sets no higher dose.

Tirzepatide · Once weekly

Subcutaneous injection in the abdomen, thigh or upper arm

2.5 mg15 mg

15 mg once weekly is the maximum for adults. For pediatric patients aged 10 years and older, the maximum is 10 mg once weekly.

Dulaglutide · Once weekly

Subcutaneous injection in the abdomen, thigh or upper arm

0.75 mg4.5 mg

4.5 mg once weekly is the maximum for adults. For pediatric patients aged 10 years and older, the maximum is 1.5 mg once weekly.

Liraglutide · Once daily

Subcutaneous injection in the abdomen, thigh or upper arm

0.6 mg1.8 mg

1.8 mg once daily is the maximum for adults and pediatric patients aged 10 years and older.

Liraglutide · Once daily

Subcutaneous injection in the abdomen, thigh or upper arm

0.6 mg3 mg

For adults, 3 mg once daily is the recommended dose; the label says to stop if it cannot be tolerated. Pediatric patients aged 12 years and older may use 2.4 mg daily if they cannot tolerate 3 mg. The label says to stop if they cannot tolerate 2.4 mg.

Orforglipron · Once daily

Tablet, swallowed whole

0.8 mg17.2 mg

17.2 mg once daily is the label maximum. When a strong CYP3A4 inhibitor is used at the same time, the label sets a lower maximum of 9 mg once daily.

Rybelsus

Semaglutide · Once daily

Tablet, swallowed whole

3 mg14 mg

14 mg once daily is the maximum. One label now covers both Rybelsus and the Ozempic tablet, and it says in its own words that the two are not swappable milligram for milligram. 7 mg of one matches 4 mg of the other, and 14 mg matches 9 mg.

Compare brand uses, forms and missed-dose instructions.

Tablet dosage guides

Tablets have their own strengths and schedules. A tablet dose does not convert directly to an injection dose.

What each kind of dose guide tells you

Approved schedule
Steps and timing from a product label. The guide keeps the stated use, age group and limits with those steps.
Trial doses
Amounts given to study groups under a research protocol. A study group’s dose is not a target for someone outside the trial.
Reported range
Amounts described in a source without an approved schedule. A report of use does not show that a dose is safe or works.
No established dose
The available sources do not establish a dose. That does not mean nobody has used or studied the compound.

How does a dose in milligrams become units on a syringe?

The unit count depends on the dose, the liquid’s strength and the syringe type. Milligrams measure the drug amount; syringe units measure a volume.

For example, a vial with 10 mg in a total of 2 mL has a strength of 5.00 mg/mL. A 2.5 mg dose takes 0.50 mL, or 50 units on a U-100 syringe. This is an arithmetic example, not a recommended dose.

Use the total drug amount and liquid volume on your vial’s label or pharmacy instructions. For a pen, follow its own dose settings. Open the peptide calculator to see the vial conversion and each step of the math.

Questions about dose schedules

Why do some compounds have a chart and others do not?

An approved schedule needs a product label that sets out the steps. Other guides may show trial doses or reported ranges. If the sources do not establish a dose, the guide states that gap.

Is a trial dose a dose anyone can follow?

No. A trial tests amounts in selected people under monitoring. Its results do not make those amounts a treatment plan for someone else. A clinician decides whether a treatment suits you.

Why can the same drug have different maximum doses?

Each product label sets the dose for its uses and age groups. The form matters too: daily tablets and weekly injections have different schedules. Use the guide for your product.

Why can the same dose need a different number of units?

A less concentrated liquid needs a larger volume to hold the same amount of drug. Syringe type also changes the unit count. Use the vial’s actual strength; do not change the mix based on a chart.

What do the evidence labels mean?

They describe the source behind the compound guide. An approved label, a human trial and a report of use support different kinds of claims. Read how we assess sources.

Each page shows the source behind its schedule. When one drug has two product labels, their schedules stay separate.

Reconstitution math for any peptide, not just this one

Enter any vial and any water volume — no compound has to be selected first.

Every tablet strength on one label

6 rules about how and when it is swallowed, taken off the label rather than summarized.

The Victoza steps, day by day

3 approved uses on the Victoza label, each dated to the FDA letter that granted it.

MOTS-c without an approved label: what exists instead

No published half-life figure was found for MOTS-c.

The newest swallowed GLP-1 schedule

No injection of it exists, so there is no other form of the same drug to weigh it against.

The Trulicity steps, week by week

3 approved uses on the Trulicity label, each dated to the FDA letter that granted it.

What returns besides the weight

Weight is not the only thing measured after stopping; waist and blood pressure were recorded too.

How long each tirzepatide step is held before the next

2 published tirzepatide dose values, each linked to the original source.

47primary sources, each with the day we read it — open the documents used on this page